In a recent analysis, Richard Newitter from Truist has adjusted the price target for Stryker Corporation (SYK, Financial), reducing it to $390, down from the previous target of $413. The recommendation to hold the shares remains unchanged. This revision comes in the context of a broader preview of the first quarter's performance across the Medical Technology sector.
Newitter indicates that Stryker's revenue and earnings appear to be more resilient compared to other segments within the sector. This relative stability is expected to maintain investor interest despite some ongoing volatility associated with tariffs. However, there is a cautious sentiment concerning the 2025 outlook as companies are expected to incorporate potential macroeconomic uncertainties into their projections.
